Both the immunosuppressant SR31747 and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian Delta8-Delta7 sterol isomerase. 1998

R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
Sanofi Recherche, F-34184 Montpellier Cédex 04, France.

SR31747 is a novel agent that elicits immunosuppressive and anti-inflammatory effects. This drug was shown to inhibit Delta8-Delta7 sterol isomerase in yeast. To test whether this enzyme could also be an SR31747 target in mammals, the binding, antiproliferative and sterol biosynthesis inhibitory properties of various drugs were studied in recombinant sterol isomerase-producing yeast cells. Our results clearly show that SR31747 is a high affinity ligand of recombinant mammalian sterol isomerase (Kd = 1 nM). Tridemorph, a sterol biosynthesis inhibitor that is widely used in agriculture as an antifungal agent, is also a powerful inhibitor of murine and human sterol isomerases (IC50 value in the nanomolar range). Some drugs, like cis-flupentixol, trifluoperazine, 7-ketocholestanol and tamoxifen, inhibit SR31747 binding only with the mammalian enzymes, whereas other drugs, like haloperidol and fenpropimorph, are much more effective with the yeast enzyme than with the mammalian ones. Emopamil, a high affinity ligand of human sterol isomerase, is inefficient in inhibiting SR31747 binding to its mammalian target, suggesting that the SR31747 and emopamil binding sites on mammalian sterol isomerase do not overlap. In contrast, SR31747 binding inhibition by tamoxifen is very efficient and competitive (IC50 value in the nanomolar range), indicating that mammalian sterol isomerase contains a so-called antiestrogen binding site. Tamoxifen is found to selectively inhibit sterol biosynthesis at the sterol isomerase step in the cells that are producing the mammalian enzyme in place of their own sterol isomerase. Finally, we also show that tridemorph, a sterol biosynthesis inhibitor widely used in agriculture as an antifungal agent, is not selective of yeast Delta8-Delta7 sterol isomerase but is also highly efficient against murine Delta8-Delta7 sterol isomerase or human Delta8-Delta7 sterol isomerase. This observation contrasts with our already published results showing that fenpropimorph, another sterol isomerase inhibitor used in agriculture, is only poorly efficient against the mammalian enzymes.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D003510 Cyclohexanes Six-carbon alicyclic hydrocarbons.
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D012441 Saccharomyces cerevisiae A species of the genus SACCHAROMYCES, family Saccharomycetaceae, order Saccharomycetales, known as "baker's" or "brewer's" yeast. The dried form is used as a dietary supplement. Baker's Yeast,Brewer's Yeast,Candida robusta,S. cerevisiae,Saccharomyces capensis,Saccharomyces italicus,Saccharomyces oviformis,Saccharomyces uvarum var. melibiosus,Yeast, Baker's,Yeast, Brewer's,Baker Yeast,S cerevisiae,Baker's Yeasts,Yeast, Baker
D013251 Steroid Isomerases Enzymes that catalyze the transposition of double bond(s) in a steroid molecule. EC 5.3.3. 3-Ketosteroid Isomerases,3-Oxosteroid Isomerases,3 Ketosteroid Isomerases,3 Oxosteroid Isomerases,Isomerases, 3-Ketosteroid,Isomerases, 3-Oxosteroid,Isomerases, Steroid
D013629 Tamoxifen One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. ICI-46,474,ICI-46474,ICI-47699,Nolvadex,Novaldex,Soltamox,Tamoxifen Citrate,Tomaxithen,Zitazonium,Citrate, Tamoxifen,ICI 46,474,ICI 46474,ICI 47699,ICI46,474,ICI46474,ICI47699

Related Publications

R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
August 2003, The Biochemical journal,
R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
September 1996, The Journal of biological chemistry,
R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
September 1998, Molecular pharmacology,
R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
November 1998, Plant molecular biology,
R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
February 2000, American journal of medical genetics,
R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
August 1969, The Biochemical journal,
R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
May 2003, Journal of medicinal chemistry,
R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
December 2000, Biochemical Society transactions,
R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
August 2001, Experimental dermatology,
R Paul, and S Silve, and N De Nys, and P H Dupuy, and C L Bouteiller, and J Rosenfeld, and P Ferrara, and G Le Fur, and P Casellas, and G Loison
October 1974, European journal of biochemistry,
Copied contents to your clipboard!